VCI Wealth Management LLC Acquires 886 Shares of Becton, Dickinson and Company $BDX

VCI Wealth Management LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 16.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,159 shares of the medical instruments supplier’s stock after purchasing an additional 886 shares during the quarter. VCI Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $1,061,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Phoenix Financial Ltd. lifted its position in shares of Becton, Dickinson and Company by 26.8% during the second quarter. Phoenix Financial Ltd. now owns 1,445 shares of the medical instruments supplier’s stock worth $249,000 after purchasing an additional 305 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Becton, Dickinson and Company by 42.3% during the second quarter. DekaBank Deutsche Girozentrale now owns 460,083 shares of the medical instruments supplier’s stock worth $79,825,000 after purchasing an additional 136,863 shares during the last quarter. Canvas Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth $470,000. Beverly Hills Private Wealth LLC raised its holdings in shares of Becton, Dickinson and Company by 9.6% in the second quarter. Beverly Hills Private Wealth LLC now owns 10,392 shares of the medical instruments supplier’s stock valued at $1,790,000 after acquiring an additional 910 shares in the last quarter. Finally, West Tower Group LLC raised its holdings in shares of Becton, Dickinson and Company by 27.8% in the second quarter. West Tower Group LLC now owns 2,300 shares of the medical instruments supplier’s stock valued at $396,000 after acquiring an additional 500 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 1,838 shares of company stock worth $348,392 in the last 90 days. 0.36% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BDX. Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Piper Sandler restated a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, October 16th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $191.28 on Tuesday. The company has a market capitalization of $54.83 billion, a PE ratio of 34.40, a P/E/G ratio of 1.48 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a 50-day simple moving average of $190.58 and a two-hundred day simple moving average of $184.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.